

PHARMACOLOGISTS WORK FOR A BETTER MEDICINE TOMORROW

F. Visioli

Department of Molecular Medicine, University of Padua, Padua, Italy

E-mail: francesco.visioli@unipd.it. **ORCID:** 0000-0002-1756-1723

Doi: 10.36118/pharmadvances.2024.62

The title of this Editorial echoes that of the latest Italian Society of Pharmacology (Società Italiana di Farmacologia, SIF) meeting, held in beautiful Sorrento, Italy, in November 2024. Even a cursory look at the program (available online) testifies to the enormous amount of work that researchers are undertaking daily to contribute to the progress of medicine, therapy, and, in turn, human health. From RNA interference (1) to molecular biology (2), from the cardiovascular system (3, 4) to the central nervous system (5), from cancer therapy (6) to gut health (2), etc., the field of pharmacology is thriving and can only get better in the future. Indeed, the word “pharmacology” now encompasses natural products (7, 8) and markers used in forensic medicine (9), basic mechanisms and clinical trials, computer science and informatics.

PharmAdvances is exactly that: *nomen-omen*. The continuous and unstoppable progress that scientific research is witnessing will certainly benefit future patients. Even though public health and preventive medicine should be at the forefront of maintaining human health, things can go wrong (as we know too well) and diseases might strike (10). This is why we need new and better drugs, as discussed at the SIF congress, via appropriate infrastructures, financial investments (often mistaken for vague expenditures), and hard work in the laboratories and in the wards. Despite the current world uncertainties, ravaging wars, financial instability, dramatic climate change, and the apparent inability of human beings to live together in peace and prosper, humanity is making big progress, and the future is always better than the present.

I encourage everyone to peruse the 42nd SIF meeting program (<https://congresso2024.sifweb.org/programma-congresso>) and find out how strong pharmacological research is becoming.

Everyone should contribute to the advancement of science, and PharmAdvances is waiting for your contributions to disseminate them worldwide.

REFERENCES

1. Tome-Carneiro J, de Las Hazas ML, Boughanem H, Bottcher Y, Cayir A, Macias Gonzalez M, et al. Up-to-date on the evidence linking miRNA-related epitranscriptomic modifications and disease settings. Can these modifications affect cross-kingdom regulation? *RNA Biol.* 2021;18(Supp 2):586-99. doi: 10.1080/15476286.2021.2002003.
2. Davalos A, Suarez Y. MiRNA-based therapy: from bench to bedside. *Pharmacol Res.* 2013;75:1-2. doi: 10.1016/j.phrs.2013.06.010.
3. Bellosta S, Corsini A. Drug interactions in cardiology: focus on statins and their combination with other lipid-lowering drugs, *Expert Opin Drug Metab Toxicol.* 2024;1-9. doi: 10.1080/17425255.2024.2402493.
4. Di Napoli A, Germana F, Colacib E, Bongiani N, Parisi F, Zucchetti P. A review of metabolic syndrome: diet, physical activity and natural remedies. *Pharmadvances.* 2024;6(1):40-56. doi: 10.36118/pharmadvances.2024.61.
5. Leo A, Scuteri D. Novel pharmacological approaches in migraine therapy, *Pharmadvances.* 2024;6(1 Special):4-6. doi: 4-610.36118/pharmadvances.2024.57.
6. Citi V, Barresi E, Piragine E, Spezzini J, Testai L, Da Settimo F, et al. Calderone, Anti-Proliferative Properties of the Novel Hybrid Drug Met-ITC, Composed of the Native Drug Metformin with the Addition of an Isothiocyanate H(2)S Donor Moiety, in Different Cancer Cell Lines. *Int J Mol Sci.* 2023;24(22):16131. doi: 10.3390/ijms242216131.
7. Visioli F. Natural products: Call for hard evidence. *Br J Pharmacol.* 2024;181(16):3010-11. doi: 10.1111/bph.16437.
8. Di Napoli A, Germani F, Domingues Da Silva S, Senatori L, Parisi F, Zucchetti P. Artichoke (*Cynara scolymus* L.): a review of its health-promoting properties., *Pharmadvances.* 2024;6(1):7-24. doi: 10.36118/pharmadvances.2023.55.
9. Condorelli G, Gozzo L, Drago F. Rethinking post-mortem tryptase: a critical analysis of its role in diagnosing anaphylactic deaths. 2024; *Pharmadvances.* 6(1):25-39. doi: 10.36118/pharmadvances.2024.60.
10. G. B. D. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. *Lancet* 2024;404(10459):1199-226. doi: 10.1016/S0140-6736(24)01867-1.